Shorts say: The phase III study of vosaroxin in acute myeloid leukemia will fail.
6. Synta Pharmaceuticals (SNTA)Short interest: 27% of float ^NBI data by YCharts
Shorts say: Synta designed the ongoing phase III lung cancer study of ganetespib around dubious, data-mined patient subgroup data. Like nearly all of these stories, the ending is tragic. 5. MannKind (MNKD) Short interest: 29% of float ^NBI data by YCharts
Shorts say: Inhaled insulin? Really? Bwhahahaha!
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts